Skip to content

TriangleGet started

← Full study record

NCT04162210 · OUTCOME

Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-baseline Relative to Baseline

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline (Day 1) and up to approximately 263 weeks

What was measured

Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Basophils (Baso), Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Volume (MCV), Erythrocytes (Ery), Hematocrit (Hct), Monocytes (Mono), Reticulocytes (Ret), Leukocytes (Leu), Eosinophils (Eosi), Lymphocytes (Lym), Neutrophils (Neu)\]

Analysis population: Safety Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Pomalidomide Plus Dexamethasone

Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	217
Pomalidomide Plus Dexamethasone	102

Reported measurements

Baso, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	69

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4	Not reported	Not reported	Not reported	Not reported

Baso, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	69

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	147	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	47	Not reported	Not reported	Not reported	Not reported

Baso, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	69

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	14	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	19	Not reported	Not reported	Not reported	Not reported

MCHC, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	213
Pomalidomide Plus Dexamethasone	97

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	69	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	30	Not reported	Not reported	Not reported	Not reported

MCHC, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	213
Pomalidomide Plus Dexamethasone	97

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	129	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	59	Not reported	Not reported	Not reported	Not reported

MCHC, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	213
Pomalidomide Plus Dexamethasone	97

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	19	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	9	Not reported	Not reported	Not reported	Not reported

MCH, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	214
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	56	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	13	Not reported	Not reported	Not reported	Not reported

MCH, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	214
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	142	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	68	Not reported	Not reported	Not reported	Not reported

MCH, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	214
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	23	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	24	Not reported	Not reported	Not reported	Not reported

MCV, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	215
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	44	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	10	Not reported	Not reported	Not reported	Not reported

MCV, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	215
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	151	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	65	Not reported	Not reported	Not reported	Not reported

MCV, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	215
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	25	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	25	Not reported	Not reported	Not reported	Not reported

Ery, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	205
Pomalidomide Plus Dexamethasone	94

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	18	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	10	Not reported	Not reported	Not reported	Not reported

Ery, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	205
Pomalidomide Plus Dexamethasone	94

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	165	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	79	Not reported	Not reported	Not reported	Not reported

Ery, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	205
Pomalidomide Plus Dexamethasone	94

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	27	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	5	Not reported	Not reported	Not reported	Not reported

Hct, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	215
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	23	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	19	Not reported	Not reported	Not reported	Not reported

Hct, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	215
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	182	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	78	Not reported	Not reported	Not reported	Not reported

Hct, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	215
Pomalidomide Plus Dexamethasone	99

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	2	Not reported	Not reported	Not reported	Not reported

Mono, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	70

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	20	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	25	Not reported	Not reported	Not reported	Not reported

Mono, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	70

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	103	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	20	Not reported	Not reported	Not reported	Not reported

Mono, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	70

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	51	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	39	Not reported	Not reported	Not reported	Not reported

Ret, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	113
Pomalidomide Plus Dexamethasone	45

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	23	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	14	Not reported	Not reported	Not reported	Not reported

Ret, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	113
Pomalidomide Plus Dexamethasone	45

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	55	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	22	Not reported	Not reported	Not reported	Not reported

Ret, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	113
Pomalidomide Plus Dexamethasone	45

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	41	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	13	Not reported	Not reported	Not reported	Not reported

Baso/Leu, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0	Not reported	Not reported	Not reported	Not reported

Baso/Leu, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	36	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	10	Not reported	Not reported	Not reported	Not reported

Baso/Leu, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	2	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	12	Not reported	Not reported	Not reported	Not reported

Eosi/Leu, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3	Not reported	Not reported	Not reported	Not reported

Eosi/Leu, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	23	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	7	Not reported	Not reported	Not reported	Not reported

Eosi/Leu, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	7	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	13	Not reported	Not reported	Not reported	Not reported

Lym/Leu, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	35
Pomalidomide Plus Dexamethasone	18

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	14	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	8	Not reported	Not reported	Not reported	Not reported

Lym/Leu, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	35
Pomalidomide Plus Dexamethasone	18

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	18	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4	Not reported	Not reported	Not reported	Not reported

Lym/Leu, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	35
Pomalidomide Plus Dexamethasone	18

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	7	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	11	Not reported	Not reported	Not reported	Not reported

Mono/Leu, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4	Not reported	Not reported	Not reported	Not reported

Mono/Leu, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	21	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	9	Not reported	Not reported	Not reported	Not reported

Mono/Leu, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	38
Pomalidomide Plus Dexamethasone	22

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	10	Not reported	Not reported	Not reported	Not reported

Neu/Leu, Decrease to Low

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	18

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	11	Not reported	Not reported	Not reported	Not reported

Neu/Leu, Change to Normal or No Change

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	18

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	17	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4	Not reported	Not reported	Not reported	Not reported

Neu/Leu, Increase to High

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	18

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11	Not reported	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	9	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
8
group Id
OG001
value
4
denoms
counts
group Id
OG000
value
168
group Id
OG001
value
69
units
Participants
title
Baso, Decrease to Low
categories
measurements
group Id
OG000
value
147
group Id
OG001
value
47
denoms
counts
group Id
OG000
value
168
group Id
OG001
value
69
units
Participants
title
Baso, Change to Normal or No Change
categories
measurements
group Id
OG000
value
14
group Id
OG001
value
19
denoms
counts
group Id
OG000
value
168
group Id
OG001
value
69
units
Participants
title
Baso, Increase to High
categories
measurements
group Id
OG000
value
69
group Id
OG001
value
30
denoms
counts
group Id
OG000
value
213
group Id
OG001
value
97
units
Participants
title
MCHC, Decrease to Low
categories
measurements
group Id
OG000
value
129
group Id
OG001
value
59
denoms
counts
group Id
OG000
value
213
group Id
OG001
value
97
units
Participants
title
MCHC, Change to Normal or No Change
categories
measurements
group Id
OG000
value
19
group Id
OG001
value
9
denoms
counts
group Id
OG000
value
213
group Id
OG001
value
97
units
Participants
title
MCHC, Increase to High
categories
measurements
group Id
OG000
value
56
group Id
OG001
value
13
denoms
counts
group Id
OG000
value
214
group Id
OG001
value
99
units
Participants
title
MCH, Decrease to Low
categories
measurements
group Id
OG000
value
142
group Id
OG001
value
68
denoms
counts
group Id
OG000
value
214
group Id
OG001
value
99
units
Participants
title
MCH, Change to Normal or No Change
categories
measurements
group Id
OG000
value
23
group Id
OG001
value
24
denoms
counts
group Id
OG000
value
214
group Id
OG001
value
99
units
Participants
title
MCH, Increase to High
categories
measurements
group Id
OG000
value
44
group Id
OG001
value
10
denoms
counts
group Id
OG000
value
215
group Id
OG001
value
99
units
Participants
title
MCV, Decrease to Low
categories
measurements
group Id
OG000
value
151
group Id
OG001
value
65
denoms
counts
group Id
OG000
value
215
group Id
OG001
value
99
units
Participants
title
MCV, Change to Normal or No Change
categories
measurements
group Id
OG000
value
25
group Id
OG001
value
25
denoms
counts
group Id
OG000
value
215
group Id
OG001
value
99
units
Participants
title
MCV, Increase to High

denoms

counts
group Id
OG000
value
217
group Id
OG001
value
102
units
Participants

description

Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Basophils (Baso), Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Volume (MCV), Erythrocytes (Ery), Hematocrit (Hct), Monocytes (Mono), Reticulocytes (Ret), Leukocytes (Leu), Eosinophils (Eosi), Lymphocytes (Lym), Neutrophils (Neu)\]

groups

description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone

param Type

COUNT_OF_PARTICIPANTS

population Description

Safety Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%

reporting Status

POSTED

time Frame

Baseline (Day 1) and up to approximately 263 weeks

title

Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-baseline Relative to Baseline

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice